Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

BMYBristol-Myers SquibbSigning up patients

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

Carcinoma, Non-Small-Cell Lung

3Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 2 insiders sold shares within a month

    Since Sep 9, 2026 · was worth 5, fading over time

    +2.6
Worry score3

Score over time

Stage
Phase 2
Patients
182 (planned)
Started
Sep 9, 2025
Main results expected
Dec 29, 2028
Fully finished
Dec 30, 2031
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Number of participants who achieve Objective Response (OR) utilizing the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Measured over: Up to 3 years after the last participant's last dose of study treatment

  • Number of participants with adverse events meeting protocol defined dose limiting toxicities (DLTs) criteria

    Measured over: Up to 28 days after the last dose of study treatment

  • Number of participants with adverse events (AE)

    Measured over: Up to 28 days after the last dose of study treatment

  • Number of participants with Serious AEs (SAEs)

    Measured over: Up to 28 days after the last dose of study treatment

  • Number of participants with treatment related AEs

    Measured over: Up to 28 days after the last dose of study treatment

  • Number of participants with treatment related SAEs

    Measured over: Up to 28 days after the last dose of study treatment

  • Number of participants with AEs leading to study treatment discontinuation

    Measured over: Up to 28 days after the last dose of study treatment

  • Number of participants with AEs leading to death

    Measured over: Up to 28 days after the last dose of study treatment

  • Number of participants with laboratory abnormalities

    Measured over: Up to 28 days after the last dose of study treatment

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT06855771 · record last updated 2026-09-18 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT06855771) ↗